NovoCure Limited NASDAQ:NVCR

NovoCure Limited stock price today

$12.059
-18.64
-60.72%
Financial Health
0
1
2
3
4
5
6
7
8
9

NovoCure Limited stock price monthly change

+70.75%
month

NovoCure Limited stock price quarterly change

+70.75%
quarter

NovoCure Limited stock price yearly change

+102.24%
year

NovoCure Limited key metrics

Market Cap
3.24B
Enterprise value
7.34B
P/E
-73.57
EV/Sales
13.65
EV/EBITDA
-122.38
Price/Sales
12.78
Price/Book
15.58
PEG ratio
1.28
EPS
-1.8
Revenue
525.65M
EBITDA
-158.63M
Income
-192.74M
Revenue Q/Q
13.35%
Revenue Y/Y
0.60%
Profit margin
-17.2%
Oper. margin
-16.64%
Gross margin
78.64%
EBIT margin
-16.64%
EBITDA margin
-30.18%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

NovoCure Limited stock price history

NovoCure Limited stock forecast

NovoCure Limited financial statements

Average Price Target
Last Year

$30

Potential upside: 148.77%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

NovoCure Limited (NASDAQ:NVCR): Profit margin
Jun 2023 126.05M -57.41M -45.55%
Sep 2023 127.32M -49.48M -38.87%
Dec 2023 133.78M -47.07M -35.19%
Mar 2024 138.50M -38.76M -27.98%
NovoCure Limited (NASDAQ:NVCR): Earnings per share (EPS)
2022-10-27 -0.23947 -0.25
2022-12-31 -0.34615 -0.35518
2023-02-23 -0.42491 -0.36
NovoCure Limited (NASDAQ:NVCR): Debt to assets
Jun 2023 1159015000 743.33M 64.13%
Sep 2023 1146353000 752.64M 65.66%
Dec 2023 1146129000 783.63M 68.37%
Mar 2024 1121429000 762.07M 67.96%
NovoCure Limited (NASDAQ:NVCR): Cash Flow
Jun 2023 -22.73M -13.89M 7.50M
Sep 2023 -19.31M 17.25M 1.17M
Dec 2023 -14.55M 98.5M 1.91M
Mar 2024 -31.57M 246.21M 213K

NovoCure Limited alternative data

NovoCure Limited (NASDAQ:NVCR): Employee count
Aug 2023 1,320
Sep 2023 1,320
Oct 2023 1,320
Nov 2023 1,320
Dec 2023 1,320
Jan 2024 1,320
Feb 2024 1,320
Mar 2024 1,453
Apr 2024 1,453
May 2024 1,453
Jun 2024 1,453
Jul 2024 1,453

NovoCure Limited other data

76.46% -1.05%
of NVCR is owned by hedge funds
79.65M -856.4K
shares is hold by hedge funds

NovoCure Limited (NASDAQ:NVCR): Insider trades (number of shares)
Period Buy Sel
Aug 2023 0 1144
Sep 2023 0 1450
Nov 2023 0 382
Feb 2024 0 4381
Mar 2024 0 5843
Jun 2024 0 2892
Transaction Date Insider Security Shares Price per share Total value Source
Option
GROENHUYSEN WILHELMUS CM officer: Chief Op.. Ordinary Shares 124,373 $22.82 $2,838,192
Option
GROENHUYSEN WILHELMUS CM officer: Chief Op.. Stock Options (Right to buy) 124,373 $7.15 $889,267
Sale
VERNON W ANTHONY director
Ordinary Shares 964 $23.89 $23,033
Sale
SCANNELL TIMOTHY J director Ordinary Shares 964 $23.89 $23,027
Sale
LEUNG GABRIEL director
Ordinary Shares 964 $23.89 $23,025
Sale
GROENHUYSEN WILHELMUS CM officer: Chief Op.. Ordinary Shares 1,217 $16.01 $19,484
Sale
LEONARD FRANK X officer: EVP, Pres., Novocure O..
Ordinary Shares 840 $16.01 $13,448
Sale
GROENHUYSEN WILHELMUS CM officer: Chief Op.. Ordinary Shares 2,107 $16.03 $33,769
Sale
LEONARD FRANK X officer: EVP, Pres., Novocure O..
Ordinary Shares 1,679 $16.03 $26,909
Sale
LEONARD FRANK X officer: EVP, Pres., Novocure O..
Ordinary Shares 2,078 $16.14 $33,545
Patent
Grant
Filling date: 8 Apr 2019 Issue date: 12 Apr 2022
Grant
Filling date: 4 Sep 2018 Issue date: 2 Nov 2021
Grant
Filling date: 13 Dec 2017 Issue date: 7 Sep 2021
Grant
Filling date: 11 Aug 2017 Issue date: 24 Aug 2021
Grant
Filling date: 17 Dec 2018 Issue date: 25 May 2021
Grant
Filling date: 3 Apr 2017 Issue date: 3 Nov 2020
Grant
Filling date: 21 Apr 2017 Issue date: 22 Sep 2020
Application
Filling date: 4 Sep 2018 Issue date: 5 Mar 2020
Grant
Filling date: 29 Jun 2017 Issue date: 15 Oct 2019
Application
Filling date: 9 Apr 2019 Issue date: 10 Oct 2019
Friday, 6 December 2024
fool.com
Thursday, 5 December 2024
fool.com
Wednesday, 4 December 2024
seekingalpha.com
Tuesday, 3 December 2024
zacks.com
Monday, 2 December 2024
seekingalpha.com
benzinga.com
investors.com
reuters.com
businesswire.com
businesswire.com
Wednesday, 27 November 2024
businesswire.com
Thursday, 21 November 2024
businesswire.com
businesswire.com
Wednesday, 30 October 2024
seekingalpha.com
zacks.com
businesswire.com
businesswire.com
Wednesday, 16 October 2024
seekingalpha.com
benzinga.com
zacks.com
Tuesday, 15 October 2024
businesswire.com
Tuesday, 1 October 2024
businesswire.com
Monday, 9 September 2024
businesswire.com
Friday, 6 September 2024
fool.com
Friday, 16 August 2024
zacks.com
Thursday, 1 August 2024
zacks.com
Tuesday, 30 July 2024
zacks.com
Friday, 26 July 2024
seekingalpha.com
Thursday, 25 July 2024
seekingalpha.com
zacks.com
  • What's the price of NovoCure Limited stock today?

    One share of NovoCure Limited stock can currently be purchased for approximately $12.06.

  • When is NovoCure Limited's next earnings date?

    Unfortunately, NovoCure Limited's (NVCR) next earnings date is currently unknown.

  • Does NovoCure Limited pay dividends?

    No, NovoCure Limited does not pay dividends.

  • How much money does NovoCure Limited make?

    NovoCure Limited has a market capitalization of 3.24B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.3% to 509.34M US dollars. NovoCure Limited made a loss 207.04M US dollars in net income (profit) last year or -$0.36 on an earnings per share basis.

  • What is NovoCure Limited's stock symbol?

    NovoCure Limited is traded on the NASDAQ under the ticker symbol "NVCR".

  • What is NovoCure Limited's primary industry?

    Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.

  • How do i buy shares of NovoCure Limited?

    Shares of NovoCure Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are NovoCure Limited's key executives?

    NovoCure Limited's management team includes the following people:

    • Mr. Asaf Danziger Pres, Chief Executive Officer & Director(age: 59, pay: $2,010,000)
    • Mr. William F. Doyle Executive Chairman(age: 63, pay: $1,830,000)
    • Mr. Wilhelmus C. M. Groenhuysen Chief Operating Officer(age: 67, pay: $1,440,000)
    • Mr. Todd C. Longsworth Gen. Counsel(age: 50, pay: $1,150,000)
    • Ms. Ashley Cordova Chief Financial Officer & Vice President of Investor Relations(age: 46, pay: $995,200)
    • Mr. Pritesh Shah Chief Commercial Officer(age: 47, pay: $946,170)
  • How many employees does NovoCure Limited have?

    As Jul 2024, NovoCure Limited employs 1,453 workers.

  • When NovoCure Limited went public?

    NovoCure Limited is publicly traded company for more then 9 years since IPO on 1 Oct 2015.

  • What is NovoCure Limited's official website?

    The official website for NovoCure Limited is novocure.com.

  • How can i contact NovoCure Limited?

    NovoCure Limited can be reached via phone at +44 1534 756700.

  • What is NovoCure Limited stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for NovoCure Limited in the last 12 months, the avarage price target is $30. The average price target represents a 148.77% change from the last price of $12.06.

NovoCure Limited company profile:

NovoCure Limited

novocure.com
Exchange:

NASDAQ

Full time employees:

1,453

Industry:

Medical - Instruments & Supplies

Sector:

Healthcare

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

No. 4 The Forum
Saint Helier, JE2 4UF

CIK: 0001645113
ISIN: JE00BYSS4X48
CUSIP: G6674U108